Efectividad de Brodalumab versus Secukinumab en el tratamiento de psoriasis en placas de moderada y grave: revisión sistemática

Abstract

Background: Psoriasis is a chronic inflammatory and autoimmune disease, presenting as well-defined erythematous and scaly plaques covered by silvery scales, affecting the elbows, knees, scalp, and lumbar region. A systematic review will be conducted with clinical trials and epidemiological data from patients with plaque psoriasis. Objective: To determine the effectiveness of Brodalumab versus Secukinumab in the treatment of moderate-to-severe plaque psoriasis in adults. Methods: The PRISMA-2020 Statement was considered; updated randomized clinical trials from the databases PubMed, SCOPUS, Web of Science, EBSCO, Cochrane, and SciELO were included. Articles published before 2019 were excluded. The risk of bias was assessed using the i National Heart, Lung, and Blood Institute (NHLBI) tool. Results: A total of 15 studies evaluating the effectiveness of Brodalumab and Secukinumab in moderate-to-severe psoriasis were analyzed. Brodalumab showed high effectiveness rates, achieving PASI75 in 93.98% of cases and PASI=0 in 68.67% at 52 weeks, while Secukinumab achieved PASI90 in 88.2% and PASI100 in 70.6% at five years. Both treatments demonstrated an adequate safety profile, with mild adverse effects. Discussion: An acceptable quality was observed in most studies; only some presented moderate quality due to classification biases and incomplete results. Conclusions: Brodalumab and Secukinumab have demonstrated high effectiveness and have been approved; the distinction lies in the amount of time required to observe the beneficial effects. Keywords: brodalumab, effectiveness, psoriasis, secukinumab, treatment